The Short Answer
Immune checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) cause myocarditis in 0.5–1.3% of patients, with fatality rates of 25–50% if untreated. Risk is highest in patients over 60, those with prior heart disease, or those receiving combination immunotherapy. Baseline troponin and echocardiography before starting therapy are essential [3][8].
Checkpoint inhibitors work by releasing the immune system's brakes on T cells, allowing them to attack cancer. Unfortunately, this also unleashes T-cell attacks on heart tissue. Myocarditis typically appears within 2–4 weeks of starting therapy but can occur months later. Troponin elevation and EKG changes are the first warning signs [3][8].
Risk factors include age > 60, prior myocardial infarction, diabetes, hypertension, and combination immunotherapy (two checkpoint inhibitors together). Patients receiving both anti-PD-1 and anti-CTLA-4 drugs have a 2–3 fold higher risk than those on monotherapy. Baseline troponin, EKG, and echocardiography help identify high-risk patients [3][8].
If myocarditis develops, the cancer drug is held immediately and high-dose corticosteroids are started. Troponin and EKG are monitored daily. Most patients recover within 2–4 weeks; 60–70% can resume cancer therapy after full recovery. Fatality is rare with prompt recognition and treatment [3][8].
Try This Today
Before starting a checkpoint inhibitor, ask your oncologist: 'What's my baseline troponin and ejection fraction?' Request troponin and EKG monitoring every 2 weeks for the first 3 months. Report chest pressure, shortness of breath, or palpitations immediately—do not wait for your next scheduled visit.